Bain Capital to Acquire Mitsubishi Tanabe Pharma for ~$3.3B
Shots:
- Bain Capital has signed to acquire Mitsubishi Tanabe Pharma in a carve-out deal from Mitsubishi Chemical Group at ~510 billion JPY (3.3 billion USD), is led by Bain Capital’s Private Equity teams in Asia, North America, and its Life Sciences team.
- The transaction is expected to close in Q3’25, pending regulatory approval, shareholder approvals, and customary closing conditions.
- Bain Capital's global Healthcare platform has multiple companies such as Avistone Pharma, Cardurion Pharma, Kailera Therapeutics, Stada and more and few which are now acquired such as Aiolos Bio (now GSK), Cereval Therapeutics (now AbbVie)
Ref: Businesswire | Image: Mitsubishi Tanabe Pharma
Related News:-
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies, FDA, EMA, and biosimilar approvals. He can be contacted at connect@pharmashots.com
